BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 26123485)

  • 1. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
    Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
    Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
    Chen CY; Weng YH; Chien KY; Lin KJ; Yeh TH; Cheng YP; Lu CS; Wang HL
    Cell Death Differ; 2012 Oct; 19(10):1623-33. PubMed ID: 22539006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.
    Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG
    Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2-G2019S mice display alterations in glutamatergic synaptic transmission in midbrain dopamine neurons.
    Skiteva O; Yao N; Sitzia G; Chergui K
    J Neurochem; 2022 Apr; 161(2):158-172. PubMed ID: 35152441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
    Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
    J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
    Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
    J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
    Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
    Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
    Cresto N; Gaillard MC; Gardier C; Gubinelli F; Diguet E; Bellet D; Legroux L; Mitja J; Auregan G; Guillermier M; Josephine C; Jan C; Dufour N; Joliot A; Hantraye P; Bonvento G; Déglon N; Bemelmans AP; Cambon K; Liot G; Brouillet E
    Neurobiol Dis; 2020 Feb; 134():104614. PubMed ID: 31605779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
    Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
    J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis.
    Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK
    Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice.
    Xiong Y; Neifert S; Karuppagounder SS; Liu Q; Stankowski JN; Lee BD; Ko HS; Lee Y; Grima JC; Mao X; Jiang H; Kang SU; Swing DA; Iacovitti L; Tessarollo L; Dawson TM; Dawson VL
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1635-1640. PubMed ID: 29386392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra.
    Han BS; Iacovitti L; Katano T; Hattori N; Seol W; Kim KS
    Neurosci Lett; 2008 Sep; 442(3):190-4. PubMed ID: 18634852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired motor coordination in Pitx3 overexpression mice.
    Kim H; Quan X; Seong Y; Kim J
    Biochem Biophys Res Commun; 2014 Apr; 446(4):1211-8. PubMed ID: 24680684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
    Xiao Q; Yang S; Le W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1645-57. PubMed ID: 26253900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor Impairments and Dopaminergic Defects Caused by Loss of Leucine-Rich Repeat Kinase Function in Mice.
    Huang G; Bloodgood DW; Kang J; Shahapal A; Chen P; Kaganovsky K; Kim JI; Ding JB; Shen J
    J Neurosci; 2022 Jun; 42(23):4755-4765. PubMed ID: 35534227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
    Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
    J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.